^
Association details:
| Biomarker: | KRAS G12V |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
Excerpt:
K-Ras lox/LSL G12V geo;RERTert/ert animals carrying lung tumors as determined by CT imaging (CT+ mice) were randomized and treated either with vehicle or with the above indicated doses of PD0332991 for 30 days. Mice were monitored for tumor development by CT at 15 days and at the end of the treatment (30 days). As illustrated in Figure 8A , animals that received vehicle increased the number of CT+ tumors by 3-fold at the 15 day time point and by 4-fold at the end of the experiment...
DOI:
https://doi.org/10.1016/j.ccr.2010.05.025
